Life-Threatening COVID-19 Vaccine-Related Side Effects: Are They Noteworthy?
-
Sina Moghaddam
,
Mina Sheikh
,
Mohammad Amin Khazeei Tabari
,
Pouya Darzi
,
Milad Rafiaei
,
Mahdieh Sheikh
Abstract
The development of COVID-19 vaccines with high efficacy has given people hope to overcome the pandemic. However, the increasing number of reports of side effects could affect the number of people who are adherent to vaccination. In most cases, pain, fever, and fatigue have been reported, which is the normal side effect of many vaccines. More serious side effects have also been reported, such as Guillain-Barre syndrome, thrombotic thrombocytopenia, anaphylaxis, and death. Although these side effects seem to be lethal, they are rare, and vaccination is the most efficient strategy to overcome this disease.
1. Khazeei Tabari MA, Iranpanah A, Bahramsoltani R, Rahimi R. Flavonoids as Promising Antiviral Agents against SARS-CoV-2 Infection: A Mechanistic Review. Molecules. 2021;26(13).
2. Khandan M, Tabari MAK, Samieefar N, Rezaei N. COVID-19, from infection to cancer. Acta Bio Medica: Atenei Parmensis. 2022;93(5).
3. Tabari MAK, Khoshhal H, Tafazoli A, Khandan M, Bagheri A. Applying computer simulations in battling with COVID-19, using pre-analyzed molecular and chemical data to face the pandemic. Informatics in Medicine Unlocked. 2020;21:100458.
4. Samieefar N, Boroujeni RY, Jamee M, Lotfi M, Golabchi MR, Afshar A, et al. Country quarantine during COVID-19: critical or not? Disaster medicine and public health preparedness. 2020:1-2.
5. Samieefar N, Boroujeni RY, Zare D, Najari S, Shiravi F, Mashhadi M, et al. What if no Specific Treatment or Vaccine Develops, in the Status of COVID-19 Pandemic? School of Medicine Students' Journal. 2020;2(2):1-2.
6. Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts. Journal of medical virology. 2022;94(4):1294-9.
7. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nature Human Behaviour. 2021;5(4):529-38.
8. Momtazmanesh S, Samieefar N, Uddin LQ, Ulrichs T, Kelishadi R, Roudenok V, et al. Socialization during the COVID-19 pandemic: the role of social and scientific networks during social distancing. Coronavirus Disease-COVID-19: Springer; 2021. p. 911-21.
9. Catching A, Capponi S, Yeh MT, Bianco S, Andino R. Examining the interplay between face mask usage, asymptomatic transmission, and social distancing on the spread of COVID-19. Scientific Reports. 2021;11(1):15998.
10. Akhondzadeh S, Shamabadi A. Medical Biotechnology in the Service of Coronavirus Vaccine Discovery and Production. Avicenna journal of medical biotechnology. 2021;13(3):105-6.
11. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nature Biotechnology. 2006;24(11):1377-83.
12. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 2021;6(1):28.
13. Administration USFaD. COVID-19 Vaccines 2021 [Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.
14. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine. 2020;383(27):2603-15.
15. Rubin R. Difficult to determine herd immunity threshold for COVID-19. Jama. 2020;324(8):732-.
16. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. New England Journal of Medicine. 2021;384(23):2187-201.
17. Göbel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain and therapy. 2021:1-22.
18. Cantarelli Rodrigues T, Hidalgo PF, Skaf AY, Serfaty A. Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration (SIRVA). Skeletal Radiology. 2021.
19. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 vaccination in a large health care organization. New England Journal of Medicine. 2021;385(23):2132-9.
20. Kashir J, Ambia AR, Shafqat A, Sajid MR, AlKattan K, Yaqinuddin A. Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccine-induced thrombotic thrombocytopenia (VITT). Journal of leukocyte biology. 2021.
21. Matarneh AS, Al-Battah AH, Farooqui K, Ghamoodi M, Alhatou M. COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clinical case reports. 2021;9(9):e04756.
22. Goin-Kochel RP. Extension: Beliefs about causes of autism and vaccine hesitancy. J Clin Pediatr Neonatol. 2021;1(2):35-6.
23. Sheikh M, Sheikh M, Samieefar N, Safari S. Factors Related to the Possibility of Accepting COVID-19 Vaccines: A Population-Based Cross-Sectional Study. Interventional Pain Medicine and Neuromodulation. 2022;2(1).
24. Zibadi S, Samieefar N, Sodeifian F, Mosavari N, Rezaei N. COVID-19 vaccination: what challenges are we going to face. Acta Bio Medica: Atenei Parmensis. 2021;92(4).
25. Pepe S, Gregory AT, Denniss AR. Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination☆. Heart, Lung and Circulation. 2021;30(10):1425-9.
26. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA. 2021.
27. Wallace M, Oliver S. COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion. 2021.
28. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. Jama. 2022;327(4):331-40.
29. Liu R, Pan J, Zhang C, Sun X. Cardiovascular complications of COVID-19 vaccines. Frontiers in Cardiovascular Medicine. 2022;9.
30. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144(6):471-84.
31. Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA network open. 2022;5(6):e2218505-e.
32. Vidula MK, Ambrose M, Glassberg H, Chokshi N, Chen T, Ferrari VA, et al. Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines. Cureus. 2021;13(6).
33. Truong DT, Dionne A, Muniz JC, McHugh KE, Portman MA, Lambert LM, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination. Circulation. 2022;145(5):345-56.
34. AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome. Reactions Weekly. 2021;1864(1):1-.
35. Ruggiero R, Balzano N, Di Napoli R, Mascolo A, Berrino PM, Rafaniello C, et al. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance. Frontiers in Immunology. 2022;13:956825.
36. Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis post Moderna COVID-19 vaccination. Kidney International. 2021.
37. Hussein A, Khalil KAL, Bawazir YM. Anti-neutrophilic cytoplasmic antibody (ANCA) vasculitis presented as pulmonary hemorrhage in a positive COVID-19 patient: a case report. Cureus. 2020;12(8).
38. Uppal NN, Kello N, Shah HH, Khanin Y, De Oleo IR, Epstein E, et al. De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19. Kidney international reports. 2020;5(11):2079.
39. Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H. Newly diagnosed glomerulonephritis during COVID-19 infection undergoing immunosuppression therapy, a case report. Iran J Kidney Dis. 2020;14(3):239-42.
40. Prabhahar A, Naidu G, Chauhan P, Sekar A, Sharma A, Sharma A, et al. ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review. Rheumatology International. 2022;42(4):749-58.
41. Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. The New England journal of medicine. 2021.
42. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. The New England journal of medicine. 2021;384(22):2092-101.
43. Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends in Cardiovascular Medicine. 2022.
44. Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nature Medicine. 2021;27(7):1290-7.
45. Cines DB, Bussel JB. SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. New England Journal of Medicine. 2021;384(23):2254-6.
46. Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood. 2021;138(4):350-3.
47. Simpson CR, Robertson C, Vasileiou E, McMenamin J, Gunson R, Ritchie LD, et al. Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data. BMJ Open. 2020;10(6):e039097.
48. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet. 2021;397(10285):1646-57.
49. Arnold DM, Nazy I, Clare R, Jaffer AM, Aubie B, Li N, et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood advances. 2017;1(25):2414-20.
50. Schifferli A, Heiri A, Imbach P, Holzhauer S, Seidel MG, Nugent D, et al. Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. Blood Advances. 2021;5(6):1617-26.
51. Moulis G, Palmaro A, Montastruc J-L, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood, The Journal of the American Society of Hematology. 2014;124(22):3308-15.
52. Grimaldi-Bensouda L, Michel M, Aubrun E, Leighton P, Viallard J-F, Adoue D, et al. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood, The Journal of the American Society of Hematology. 2012;120(25):4938-44.
53. (WHO). WHO. COVID-19 vaccine safety surveillance manual. [Internet]. 2023 [cited 2023 Oct 10]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine-safety-surveillance-manual.
54. Food U, Administration D. Coronavirus (COVID-19) update: FDA limits use of Janssen COVID-19 vaccine to certain individuals. FDA news release US Food and Drug Administration, Bethesda, MD. 2022.
55. Yang J, Li H, Hu S, Zhou Y. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19. Aging. 2020;12(8):6518-35.
56. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination. The New England journal of medicine. 2021;384(20):1964-5.
57. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. The New England journal of medicine. 2021;384(22):2124-30.
58. Verschuur J, Koks EE, Hall JW. Global economic impacts of COVID-19 lockdown measures stand out in high-frequency shipping data. PLOS ONE. 2021;16(4):e0248818.
59. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. The New England journal of medicine. 2021;384(23):2202-11.
60. Lippi G, Favaloro EJ, editors. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Seminars in Thrombosis and Hemostasis; 2022: Thieme Medical Publishers, Inc.
61. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396(10249):467-78.
62. Faksova K, Walsh D, Jiang Y, Griffin J, Phillips A, Gentile A, et al. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024;42(9):2200-11.
63. Hviid A, Hansen JV, Thiesson EM, Wohlfahrt J. Association of AZD1222 and BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic events in frontline personnel: a retrospective cohort study. Annals of internal medicine. 2022;175(4):541-6.
64. Zakaria Z, Sapiai NA, Ghani ARI. Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine. Acta neurochirurgica. 2021;163(8):2359-62.
65. Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Internal and emergency medicine. 2021;16:803-4.
66. Sung JG, Sobieszczyk PS, Bhatt DL. Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination. The American Journal of Cardiology. 2021.
67. Chatterjee S, Ojha UK, Vardhan B, Tiwari A. Myocardial infarction after COVID-19 vaccination-casual or causal? Diabetes & Metabolic Syndrome. 2021.
68. Tobaiqy M, Elkout H, MacLure K. Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines. 2021;9(4).
69. Mohseni Afshar Z, Babazadeh A, Janbakhsh A, Afsharian M, Saleki K, Barary M, et al. Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: A clinical dilemma for clinicians and patients. Reviews in Medical Virology. 2021;n/a(n/a):e2273.
70. Brazete C, Aguiar A, Furtado I, Duarte R. Thrombotic events and COVID-19 vaccines. The International Journal of Tuberculosis and Lung Disease. 2021;25(9):701-7.
71. Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. The Lancet Haematology. 2022;9(1):e73-e80.
72. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. New England Journal of Medicine. 2021;384(22):2092-101.
73. Principi N, Esposito S. Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome. Vaccine. 2019;37(37):5544-50.
74. Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I, Baleeiro Rodrigues Silva P, Freitas Barboza IC, Vieira Silveira CG, et al. Guillain‐Barre syndrome following COVID‐19 vaccines: a scoping review. Acta Neurologica Scandinavica. 2022;145(4):393-8.
75. Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Annals of neurology. 2021;90(2):312-4.
76. FDA. Coronavirus (COVID-19) Update: July 13, 2021 2021 [Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021.
77. Agency EM. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021 2021.
78. Canada PHAo. Reports of Guillain-Barré Syndrome following adenovirus vector COVID-19 vaccines. 2021.
79. Agency EM. COVID-19 Vaccine Janssen: Guillain-Barré syndrome listed as a very rare side effect 2021 [Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-guillain-barre-syndrome-listed-very-rare-side-effect.
80. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and drug safety. 2001;10(6):483-6.
81. Romio S, Weibel D, Dieleman JP, Olberg HK, De Vries CS, Sammon C, et al. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PloS one. 2014;9(1):e82222.
82. COVID W. vaccine tracker and landscape. 16 June 2021.
83. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947-53.
84. Cirillo N. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2021;50(4):424-7.
85. Cirillo N, Doan R. The association between COVID-19 vaccination and Bell's palsy. The Lancet Infectious Diseases. 2022;22(1):5-6.
86. Lassaletta L, Sánchez-Cuadrado I, Mato-Patino T, Peñarrocha J, Angélica Rivera-Núñez M, María Torres Santos-Olmo R, et al. Has Coranavirus Disease 2019 Changed the Incidence and Outcome of Bell's Palsy? J Int Adv Otol. 2024;20(1):19-25.
87. Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, et al. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. The Lancet Infectious Diseases. 2021.
88. Mussatto CC, Sokol J, Alapati N. Bell's palsy following COVID-19 vaccine administration in HIV+ patient. American Journal of Ophthalmology Case Reports. 2022;25:101259.
89. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine. 2020;383(27):2603-15.
90. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021;384(5):403-16.
91. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2021;397(10269):99-111.
92. Cirillo N, Doan R. Bell's palsy and SARS-CoV-2 vaccines-an unfolding story. The Lancet Infectious diseases. 2021;21(9):1210-1.
93. Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, et al. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA internal medicine. 2021.
94. Tamaki A, Cabrera CI, Li S, Rabbani C, Thuener JE, Rezaee RP, et al. Incidence of Bell Palsy in Patients With COVID-19. JAMA otolaryngology-- head & neck surgery. 2021;147(8):767-8.
95. Shemer A, Pras E, Einan-Lifshitz A, Dubinsky-Pertzov B, Hecht I. Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study. JAMA otolaryngology-- head & neck surgery. 2021;147(8):739-43.
96. Wan EYF, Chui CSL, Ng VWS, Wang Y, Yan VKC, Lam ICH, et al. mRNA (BNT162b2) COVID-19 vaccination increased risk of Bell's palsy: a nested case control and self-controlled case series study. Clin infect dis. 2022.
97. Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nature Medicine. 2021:1-8.
98. Kato Y, Osada T, Araki N, Takahashi S. Aseptic Meningitis after BNT-162b2 COVID-19 Vaccination: Case Report and Literature Review. The Keio Journal of Medicine. 2023;72(4):102-5.
99. Atefi A, Ghanaatpisheh A, Ghasemi A, Haghshenas H, Eyvani K, Bakhshi A, et al. Meningitis after COVID-19 vaccination, a systematic review of case reports and case series. BMC Infectious Diseases. 2024;24(1):1138.
100. Saito K, Shimizu T, Suzuki-Inoue K, Ishida T, Wada Y. Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021:1-3.
101. Chan ACY, Tan BYQ, Goh Y, Tan SSY, Tambyah PA. Aseptic meningitis after BNT-162b2 COVID-19 vaccination. Brain, Behavior, & Immunity - Health. 2022;19:100406.
102. Dupon V, Arnaert S, Van Haute E, Vulsteke F, Diet G, De Schoenmakere G. Aseptic meningitis after SARS-CoV-2 Pfizer/BioNTech vaccination. Acta Clinica Belgica. 2022;77(6):976-9.
103. Zavari A, Hamidabad NM, Hassanzadeh M. Aseptic meningitis following AZD1222 COVID-19 vaccination. The American Journal of Emergency Medicine. 2022;55:225.e5-.e6.
104. Kang HS, Kim JE, Yoo JR, Oh H, Kim M, Kim YR, et al. Aseptic Meningitis Following Second Dose of an mRNA Coronavirus Disease 2019 Vaccine in a Healthy Male: Case Report and Literature Review. Infect Chemother. 2022;54(1):189-94.
105. Lee JK. Aseptic Meningitis Following the Second Dose of Comirnaty Vaccination in an Adolescent Patient: A Case Report. The Pediatric Infectious Disease Journal. 2022;41(2).
106. Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature medicine. 2021;27(12):2144-53.
107. Torrealba-Acosta G, Martin JC, Huttenbach Y, Garcia CR, Sohail MR, Agarwal SK, et al. Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine. BMJ Case Reports CP. 2021;14(7):e243173.
108. Zuhorn F, Graf T, Klingebiel R, Schäbitz WR, Rogalewski A. Postvaccinal Encephalitis after ChAdOx1 nCov-19. Annals of neurology. 2021;90(3):506-11.
109. Rinaldi V, Bellucci G, Romano A, Bozzao A, Salvetti M. ADEM after ChAdOx1 nCoV-19 vaccine: A case report. Multiple Sclerosis Journal. 2022;28(7):1151-4.
110. Al-Quliti K, Qureshi A, Quadri M, Abdulhameed B, Alanazi A, Alhujeily R. Acute Demyelinating Encephalomyelitis Post-COVID-19 Vaccination: A Case Report and Literature Review. Diseases. 2022;10(1):13.
111. Yazdanpanah F, Iranpour P, Haseli S, Poursadeghfard M, Yarmahmoodi F. Acute disseminated encephalomyelitis (ADEM) after SARS- CoV-2 vaccination: A case report. Radiology Case Reports. 2022;17(5):1789-93.
112. Cao L, Ren L. Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. Acta Neurologica Belgica. 2022;122(3):793-5.
113. Shyu S, Fan H-T, Shang S-T, Chan J-S, Chiang W-F, Chiu C-C, et al. Clinical Manifestation, Management, and Outcomes in Patients with COVID-19 Vaccine-Induced Acute Encephalitis: Two Case Reports and a Literature Review. Vaccines. 2022;10(8):1230.
114. Al-Mayhani T, Saber S, Stubbs MJ, Losseff NA, Perry RJ, Simister RJ, et al. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopaenia. Journal of Neurology, Neurosurgery & Psychiatry. 2021.
115. Taquet M, Husain M, Geddes JR, Luciano S, Harrison PJ. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. medRxiv. 2021.
116. Markus HS. Ischaemic stroke can follow COVID-19 vaccination but is much more common with COVID-19 infection itself. BMJ Publishing Group Ltd; 2021.
117. Kakovan M, Shirkouhi SG, Zarei M, Andalib S. Stroke associated with COVID-19 vaccines. Journal of Stroke and Cerebrovascular Diseases. 2022:106440.
118. Cabral G, Gonçalves C, Serrazina F, Sá F. MRI negative myelitis induced by Pfizer-BioNTech COVID-19 vaccine. Journal of Clinical Neurology (Seoul, Korea). 2022;18(1):120.
119. Dams L, Kraemer M, Becker J. MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination. Multiple Sclerosis Journal. 2022;28(7):1159-62.
120. Goss AL, Samudralwar RD, Das RR, Nath A. ANA investigates: neurological complications of COVID‐19 vaccines. Annals of neurology. 2021;89(5):856.
121. Lim E, Kim YH, Jeong N-Y, Kim S-H, Won H, Bae J-S, et al. The association between acute transverse myelitis and COVID-19 vaccination in Korea: Self-controlled case series study. European Journal of Neurology. 2025;32(1):e70020.
122. Kildegaard H, Ladebo L, Andersen JH, Jensen PB, Rasmussen L, Damkier P, et al. Risk of appendicitis after mRNA COVID-19 vaccination in a Danish population. JAMA internal medicine. 2022;182(6):684-6.
123. Mitchell J, Yue Q-Y. Appendicitis as a possible safety signal for the COVID-19 vaccines. Vaccine: X. 2021;9:100122.
124. FDA Staff Find Few Faults with Pfizer-BioNTech COVID-19 Vax December 8, 2020 [Available from:https://www.medpagetoday.com/infectiousdisease/covid19/90088.
125. Ramson DM, Gao H, Penny-Dimri JC, Liu Z, Khong JN, Caruana CB, et al. Duration of post-operative antibiotic treatment in acute complicated appendicitis: systematic review and meta-analysis. ANZ J Surg. 2021;91(7-8):1397-404.
126. Shahmoradi MK, Zarei F, Beiranvand M, Hosseinnia Z. A retrospective descriptive study based on etiology of appendicitis among patients undergoing appendectomy. International Journal of Surgery Open. 2021;31:100326.
127. Téoule P, Laffolie J, Rolle U, Reissfelder C. Acute Appendicitis in Childhood and Adulthood. Dtsch Arztebl Int. 2020;117(45):764-74.
128. Kawano H, Yamamoto N, Kurohama H, Okano S, Kurobe M, Honda T, et al. Fulminant Myocarditis and Acute Appendicitis after COVID-19 Vaccination. Intern Med. 2023;62(3):411-7.
129. Marconi E, Crescioli G, Bonaiuti R, Pugliese L, Santi R, Nesi G, et al. Acute appendicitis in a patient immunised with COVID-19 vaccine: A case report with morphological analysis. Br J Clin Pharmacol. 2023;89(2):551-5.
130. Oganesyan A, Schäfer M, Lesh C. Acute appendicitis following the COVID-19 vaccine. Journal of Surgical Case Reports. 2022;2022(6).
131. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. The New England journal of medicine. 2021;385(12):1078-90.
132. Ljung R, Pihlström N, Sundström A. Risk of appendicitis after SARS-CoV-2 infection and SARS-CoV-2 vaccination. Br J Surg. 2022;109(8):775-6.
133. Muhammad Yusoff F, Wong KK, Mohd Redzwan N. Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity. 2020;53(1):8-20.
134. Quint E, Kukeev I, Hazan I, Grupel D, Dukhno O, Osyntsov A, et al. Clinical characteristics of SARS-CoV-2 vaccine-related acute appendicitis. Can J Surg. 2023;66(3):E304-e9.
135. Mj EO, Juanes de Toledo B. Pfizer-BioNTech, la primera vacuna ARNm contra la COVID-19, parece segura y eficaz.
136. Wong CKH, Mak LY, Au ICH, Lai FTT, Li X, Wan EYF, et al. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. Journal of hepatology. 2022;77(5):1339-48.
137. Hines A, Shen JG, Olazagasti C, Shams S. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine. BMJ Case Reports CP. 2021;14(7):e242678.
138. Shlomovitz E, Davies W, Cairns E, Brintnell WC, Goldszmidt M, Dresser GK. Severe necrotizing pancreatitis following combined hepatitis A and B vaccination. Cmaj. 2007;176(3):339-42.
139. Bizjak M, Bruck O, Praprotnik S, Dahan S, Shoenfeld Y. Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry. Immunologic research. 2017;65(1):164-7.
140. COVID P-B. vaccine (BNT162, PF-07302048). Vaccines and Related Biological Products Advisory Committee briefing document. December 10, 2020.
141. Ozaka S, Kodera T, Ariki S, Kobayashi T, Murakami K. Acute pancreatitis soon after COVID-19 vaccination: A case report. Medicine. 2022;101(2).
142. Cahuapaza-Gutierrez NL, Pajuelo-Vasquez R, Quiroz-Narvaez C, Rioja-Torres F, Quispe-Andahua M, Runzer-Colmenares FM. Acute abdomen following COVID-19 vaccination: a systematic review. Clin Exp Vaccine Res. 2024;13(1):42-53.
143. Giles C. Covid-19 vaccines and periods. New Scientist. 2021;250(3341):14.
144. Kurdoğlu Z. Do the COVID-19 Vaccines Cause Menstrual Irregularities?
145. Zauche LH, Wallace B, Smoots AN, Olson CK, Oduyebo T, Kim SY, et al. Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21. 2021.
146. Girardelli S, Mullins E, Lees CC. COVID-19 and pregnancy: lessons from 2020. Early Human Development. 2021:105460.
147. Leclerc S, Royal V, Lamarche C, Laurin L-P. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report. American Journal of Kidney Diseases. 2021.
148. Ruebner RL, Fadrowski JJ. Tubulointerstitial nephritis. Pediatric Clinics. 2019;66(1):111-9.
149. Sowpati DT, Munigela A, Banu S, Siva AB, Sasikala M, Nutalapati C, et al. Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2. medRxiv. 2021.
150. Chauhan S, Meshram HS, Kute V, Patel H, Banerjee S, Engineer D, et al. SARS-CoV-2 infection in chronic kidney disease patients vaccinated with Oxford/AstraZeneca COVID-19 vaccine: initial Indian experience. Clinical Kidney Journal. 2021.
151. Anderegg MA, Liu M, Saganas C, Montani M, Vogt B, Huynh-Do U, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney international. 2021.
152. Holzworth A, Couchot P, Cruz-Knight W, Brucculeri M. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine. Kidney international. 2021;100(2):463-4.
153. Salem F, Rein J, Yu SM-W, Abramson M, Cravedi P, Chung M. Report of Three Cases of Minimal Change Disease Following the Second Dose of mRNA SARS-CoV-2 Vaccine. Kidney International Reports. 2021.
154. Izzedine H, Bonilla M, Jhaveri KD. Nephrotic syndrome and vasculitis following SARS-CoV-2 Vaccine: True association or circumstantial? Nephrol Dial Transplant. 2021:gfab215.
155. Lebedev L, Sapojnikov M, Wechsler A, Varadi-Levi R, Zamir D, Tobar A, et al. Minimal change disease following the Pfizer-BioNTech COVID-19 Vaccine. American Journal of Kidney Diseases. 2021.
156. Mancianti N, Guarnieri A, Tripodi S, Salvo DP, Garosi G. Minimal change disease following vaccination for SARS-CoV-2. Journal of Nephrology. 2021:1-2.
157. Weijers J, Alvarez C, Hermans MM. Post-vaccinal minimal change disease. Kidney International. 2021;100(2):459-61.
158. Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. American Journal of Kidney Diseases. 2021.
159. D’Agati VD, Kudose S, Bomback AS, Adamidis A, Tartini A. Minimal Change Disease and AKI following the Pfizer-BioNTech COVID-19 Vaccine. Kidney international. 2021.
160. Zhang J, Cao J, Ye Q. Renal Side Effects of COVID-19 Vaccination. Vaccines. 2022;10(11):1783.
161. Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2. Vaccines. 2021;9(6):572.
162. Rodríguez-Jiménez P, Chicharro P, Cabrera L-M, Seguí M, Morales-Caballero Á, Llamas-Velasco M, et al. Varicella-Zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Reports. 2021;12:58-9.
163. Cazzola M, Rogliani P, Mazzeo F, Matera MG. Controversy surrounding the Sputnik V vaccine. Respiratory medicine. 2021:106569.
164. Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5 vectored vaccines: a cautionary tale. The Lancet. 2020;396(10260):e68-e9.
165. Mishra SB, Mahendradas P, Kawali A, Sanjay S, Shetty R. Reactivation of varicella zoster infection presenting as acute retinal necrosis post COVID 19 vaccination in an Asian Indian male. European Journal of Ophthalmology. 2023;33(1):NP32-NP6.
166. Cabanillas B, Novak N. Allergy to COVID-19 vaccines: a current update. Allergology International. 2021;70(3):313-8.
167. Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines. 2021;9(3):221.
168. Lopes NT, Pinilla CEO, Gerbase AC. Erythema multiforme after CoronaVac vaccination. Journal of the European Academy of Dermatology and Venereology. 2021.
169. Farinazzo E, Ponis G, Zelin E, Errichetti E, Stinco G, Pinzani C, et al. Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from North‐East Italy. Journal of the European Academy of Dermatology and Venereology. 2021.
170. Capassoni M, Ketabchi S, Cassisa A, Caramelli R, Molinu AA, Galluccio F, et al. AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: A case report. Journal of Medical Virology. 2021;93(10):5718-20.
171. Cazzato G, Romita P, Foti C, Cimmino A, Colagrande A, Arezzo F, et al. Purpuric Skin Rash in a Patient Undergoing Pfizer-BioNTech COVID-19 Vaccination: Histological Evaluation and Perspectives. Vaccines. 2021;9(7):760.
172. Robinson LB, Fu X, Hashimoto D, Wickner P, Shenoy ES, Landman AB, et al. Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines. JAMA Dermatology. 2021;157(8):1000-2.
173. Abdulla ZA, Al-Bashir SM, Al-Salih NS, Aldamen AA, Abdulazeez MZ. A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development. Pathogens. 2021;10(7):788.
174. Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. Academic Radiology. 2021.
175. Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18 F] FDG PET-CT and relevance to study interpretation. European journal of nuclear medicine and molecular imaging. 2021;48:1854-63.
176. Ciliberti V, Maffei E, Giudice V, Ciancia G, Zeppa P, Caputo A. COVID-19 vaccine-associated lymphadenopathy: a review. Infez Med. 2024;32(2):119-30.
177. Juhel BC, Brunelle CL, Bernstein MC, Smith LH, Jung AW, Ababneh HS, et al. Side effects of COVID-19 vaccinations in patients treated for breast cancer. Clinical and Experimental Medicine. 2023:1-10.
178. (CDC) CfDPaC. Key things to know about COVID-19 vaccines. Accessed 29th May 2021.
179. (WHO) WHO. Covax. Accessed 28th May 2021.
180. Cines DB, Bussel JB. SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia. Mass Medical Soc; 2021.
181. Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet. 2021;397(10269):72-4.
182. Torjesen I. Covid-19: Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds. BMJ: British Medical Journal (Online). 2021;373.
2. Khandan M, Tabari MAK, Samieefar N, Rezaei N. COVID-19, from infection to cancer. Acta Bio Medica: Atenei Parmensis. 2022;93(5).
3. Tabari MAK, Khoshhal H, Tafazoli A, Khandan M, Bagheri A. Applying computer simulations in battling with COVID-19, using pre-analyzed molecular and chemical data to face the pandemic. Informatics in Medicine Unlocked. 2020;21:100458.
4. Samieefar N, Boroujeni RY, Jamee M, Lotfi M, Golabchi MR, Afshar A, et al. Country quarantine during COVID-19: critical or not? Disaster medicine and public health preparedness. 2020:1-2.
5. Samieefar N, Boroujeni RY, Zare D, Najari S, Shiravi F, Mashhadi M, et al. What if no Specific Treatment or Vaccine Develops, in the Status of COVID-19 Pandemic? School of Medicine Students' Journal. 2020;2(2):1-2.
6. Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts. Journal of medical virology. 2022;94(4):1294-9.
7. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nature Human Behaviour. 2021;5(4):529-38.
8. Momtazmanesh S, Samieefar N, Uddin LQ, Ulrichs T, Kelishadi R, Roudenok V, et al. Socialization during the COVID-19 pandemic: the role of social and scientific networks during social distancing. Coronavirus Disease-COVID-19: Springer; 2021. p. 911-21.
9. Catching A, Capponi S, Yeh MT, Bianco S, Andino R. Examining the interplay between face mask usage, asymptomatic transmission, and social distancing on the spread of COVID-19. Scientific Reports. 2021;11(1):15998.
10. Akhondzadeh S, Shamabadi A. Medical Biotechnology in the Service of Coronavirus Vaccine Discovery and Production. Avicenna journal of medical biotechnology. 2021;13(3):105-6.
11. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nature Biotechnology. 2006;24(11):1377-83.
12. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 2021;6(1):28.
13. Administration USFaD. COVID-19 Vaccines 2021 [Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.
14. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine. 2020;383(27):2603-15.
15. Rubin R. Difficult to determine herd immunity threshold for COVID-19. Jama. 2020;324(8):732-.
16. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. New England Journal of Medicine. 2021;384(23):2187-201.
17. Göbel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain and therapy. 2021:1-22.
18. Cantarelli Rodrigues T, Hidalgo PF, Skaf AY, Serfaty A. Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration (SIRVA). Skeletal Radiology. 2021.
19. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 vaccination in a large health care organization. New England Journal of Medicine. 2021;385(23):2132-9.
20. Kashir J, Ambia AR, Shafqat A, Sajid MR, AlKattan K, Yaqinuddin A. Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccine-induced thrombotic thrombocytopenia (VITT). Journal of leukocyte biology. 2021.
21. Matarneh AS, Al-Battah AH, Farooqui K, Ghamoodi M, Alhatou M. COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clinical case reports. 2021;9(9):e04756.
22. Goin-Kochel RP. Extension: Beliefs about causes of autism and vaccine hesitancy. J Clin Pediatr Neonatol. 2021;1(2):35-6.
23. Sheikh M, Sheikh M, Samieefar N, Safari S. Factors Related to the Possibility of Accepting COVID-19 Vaccines: A Population-Based Cross-Sectional Study. Interventional Pain Medicine and Neuromodulation. 2022;2(1).
24. Zibadi S, Samieefar N, Sodeifian F, Mosavari N, Rezaei N. COVID-19 vaccination: what challenges are we going to face. Acta Bio Medica: Atenei Parmensis. 2021;92(4).
25. Pepe S, Gregory AT, Denniss AR. Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination☆. Heart, Lung and Circulation. 2021;30(10):1425-9.
26. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA. 2021.
27. Wallace M, Oliver S. COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion. 2021.
28. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. Jama. 2022;327(4):331-40.
29. Liu R, Pan J, Zhang C, Sun X. Cardiovascular complications of COVID-19 vaccines. Frontiers in Cardiovascular Medicine. 2022;9.
30. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144(6):471-84.
31. Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA network open. 2022;5(6):e2218505-e.
32. Vidula MK, Ambrose M, Glassberg H, Chokshi N, Chen T, Ferrari VA, et al. Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines. Cureus. 2021;13(6).
33. Truong DT, Dionne A, Muniz JC, McHugh KE, Portman MA, Lambert LM, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination. Circulation. 2022;145(5):345-56.
34. AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome. Reactions Weekly. 2021;1864(1):1-.
35. Ruggiero R, Balzano N, Di Napoli R, Mascolo A, Berrino PM, Rafaniello C, et al. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance. Frontiers in Immunology. 2022;13:956825.
36. Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis post Moderna COVID-19 vaccination. Kidney International. 2021.
37. Hussein A, Khalil KAL, Bawazir YM. Anti-neutrophilic cytoplasmic antibody (ANCA) vasculitis presented as pulmonary hemorrhage in a positive COVID-19 patient: a case report. Cureus. 2020;12(8).
38. Uppal NN, Kello N, Shah HH, Khanin Y, De Oleo IR, Epstein E, et al. De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19. Kidney international reports. 2020;5(11):2079.
39. Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H. Newly diagnosed glomerulonephritis during COVID-19 infection undergoing immunosuppression therapy, a case report. Iran J Kidney Dis. 2020;14(3):239-42.
40. Prabhahar A, Naidu G, Chauhan P, Sekar A, Sharma A, Sharma A, et al. ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review. Rheumatology International. 2022;42(4):749-58.
41. Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. The New England journal of medicine. 2021.
42. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. The New England journal of medicine. 2021;384(22):2092-101.
43. Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends in Cardiovascular Medicine. 2022.
44. Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nature Medicine. 2021;27(7):1290-7.
45. Cines DB, Bussel JB. SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. New England Journal of Medicine. 2021;384(23):2254-6.
46. Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood. 2021;138(4):350-3.
47. Simpson CR, Robertson C, Vasileiou E, McMenamin J, Gunson R, Ritchie LD, et al. Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data. BMJ Open. 2020;10(6):e039097.
48. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet. 2021;397(10285):1646-57.
49. Arnold DM, Nazy I, Clare R, Jaffer AM, Aubie B, Li N, et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood advances. 2017;1(25):2414-20.
50. Schifferli A, Heiri A, Imbach P, Holzhauer S, Seidel MG, Nugent D, et al. Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. Blood Advances. 2021;5(6):1617-26.
51. Moulis G, Palmaro A, Montastruc J-L, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood, The Journal of the American Society of Hematology. 2014;124(22):3308-15.
52. Grimaldi-Bensouda L, Michel M, Aubrun E, Leighton P, Viallard J-F, Adoue D, et al. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood, The Journal of the American Society of Hematology. 2012;120(25):4938-44.
53. (WHO). WHO. COVID-19 vaccine safety surveillance manual. [Internet]. 2023 [cited 2023 Oct 10]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine-safety-surveillance-manual.
54. Food U, Administration D. Coronavirus (COVID-19) update: FDA limits use of Janssen COVID-19 vaccine to certain individuals. FDA news release US Food and Drug Administration, Bethesda, MD. 2022.
55. Yang J, Li H, Hu S, Zhou Y. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19. Aging. 2020;12(8):6518-35.
56. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination. The New England journal of medicine. 2021;384(20):1964-5.
57. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. The New England journal of medicine. 2021;384(22):2124-30.
58. Verschuur J, Koks EE, Hall JW. Global economic impacts of COVID-19 lockdown measures stand out in high-frequency shipping data. PLOS ONE. 2021;16(4):e0248818.
59. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. The New England journal of medicine. 2021;384(23):2202-11.
60. Lippi G, Favaloro EJ, editors. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Seminars in Thrombosis and Hemostasis; 2022: Thieme Medical Publishers, Inc.
61. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396(10249):467-78.
62. Faksova K, Walsh D, Jiang Y, Griffin J, Phillips A, Gentile A, et al. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024;42(9):2200-11.
63. Hviid A, Hansen JV, Thiesson EM, Wohlfahrt J. Association of AZD1222 and BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic events in frontline personnel: a retrospective cohort study. Annals of internal medicine. 2022;175(4):541-6.
64. Zakaria Z, Sapiai NA, Ghani ARI. Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine. Acta neurochirurgica. 2021;163(8):2359-62.
65. Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Internal and emergency medicine. 2021;16:803-4.
66. Sung JG, Sobieszczyk PS, Bhatt DL. Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination. The American Journal of Cardiology. 2021.
67. Chatterjee S, Ojha UK, Vardhan B, Tiwari A. Myocardial infarction after COVID-19 vaccination-casual or causal? Diabetes & Metabolic Syndrome. 2021.
68. Tobaiqy M, Elkout H, MacLure K. Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines. 2021;9(4).
69. Mohseni Afshar Z, Babazadeh A, Janbakhsh A, Afsharian M, Saleki K, Barary M, et al. Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: A clinical dilemma for clinicians and patients. Reviews in Medical Virology. 2021;n/a(n/a):e2273.
70. Brazete C, Aguiar A, Furtado I, Duarte R. Thrombotic events and COVID-19 vaccines. The International Journal of Tuberculosis and Lung Disease. 2021;25(9):701-7.
71. Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. The Lancet Haematology. 2022;9(1):e73-e80.
72. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. New England Journal of Medicine. 2021;384(22):2092-101.
73. Principi N, Esposito S. Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome. Vaccine. 2019;37(37):5544-50.
74. Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I, Baleeiro Rodrigues Silva P, Freitas Barboza IC, Vieira Silveira CG, et al. Guillain‐Barre syndrome following COVID‐19 vaccines: a scoping review. Acta Neurologica Scandinavica. 2022;145(4):393-8.
75. Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Annals of neurology. 2021;90(2):312-4.
76. FDA. Coronavirus (COVID-19) Update: July 13, 2021 2021 [Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021.
77. Agency EM. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021 2021.
78. Canada PHAo. Reports of Guillain-Barré Syndrome following adenovirus vector COVID-19 vaccines. 2021.
79. Agency EM. COVID-19 Vaccine Janssen: Guillain-Barré syndrome listed as a very rare side effect 2021 [Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-guillain-barre-syndrome-listed-very-rare-side-effect.
80. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and drug safety. 2001;10(6):483-6.
81. Romio S, Weibel D, Dieleman JP, Olberg HK, De Vries CS, Sammon C, et al. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PloS one. 2014;9(1):e82222.
82. COVID W. vaccine tracker and landscape. 16 June 2021.
83. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947-53.
84. Cirillo N. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2021;50(4):424-7.
85. Cirillo N, Doan R. The association between COVID-19 vaccination and Bell's palsy. The Lancet Infectious Diseases. 2022;22(1):5-6.
86. Lassaletta L, Sánchez-Cuadrado I, Mato-Patino T, Peñarrocha J, Angélica Rivera-Núñez M, María Torres Santos-Olmo R, et al. Has Coranavirus Disease 2019 Changed the Incidence and Outcome of Bell's Palsy? J Int Adv Otol. 2024;20(1):19-25.
87. Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, et al. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. The Lancet Infectious Diseases. 2021.
88. Mussatto CC, Sokol J, Alapati N. Bell's palsy following COVID-19 vaccine administration in HIV+ patient. American Journal of Ophthalmology Case Reports. 2022;25:101259.
89. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine. 2020;383(27):2603-15.
90. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021;384(5):403-16.
91. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2021;397(10269):99-111.
92. Cirillo N, Doan R. Bell's palsy and SARS-CoV-2 vaccines-an unfolding story. The Lancet Infectious diseases. 2021;21(9):1210-1.
93. Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, et al. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA internal medicine. 2021.
94. Tamaki A, Cabrera CI, Li S, Rabbani C, Thuener JE, Rezaee RP, et al. Incidence of Bell Palsy in Patients With COVID-19. JAMA otolaryngology-- head & neck surgery. 2021;147(8):767-8.
95. Shemer A, Pras E, Einan-Lifshitz A, Dubinsky-Pertzov B, Hecht I. Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study. JAMA otolaryngology-- head & neck surgery. 2021;147(8):739-43.
96. Wan EYF, Chui CSL, Ng VWS, Wang Y, Yan VKC, Lam ICH, et al. mRNA (BNT162b2) COVID-19 vaccination increased risk of Bell's palsy: a nested case control and self-controlled case series study. Clin infect dis. 2022.
97. Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nature Medicine. 2021:1-8.
98. Kato Y, Osada T, Araki N, Takahashi S. Aseptic Meningitis after BNT-162b2 COVID-19 Vaccination: Case Report and Literature Review. The Keio Journal of Medicine. 2023;72(4):102-5.
99. Atefi A, Ghanaatpisheh A, Ghasemi A, Haghshenas H, Eyvani K, Bakhshi A, et al. Meningitis after COVID-19 vaccination, a systematic review of case reports and case series. BMC Infectious Diseases. 2024;24(1):1138.
100. Saito K, Shimizu T, Suzuki-Inoue K, Ishida T, Wada Y. Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021:1-3.
101. Chan ACY, Tan BYQ, Goh Y, Tan SSY, Tambyah PA. Aseptic meningitis after BNT-162b2 COVID-19 vaccination. Brain, Behavior, & Immunity - Health. 2022;19:100406.
102. Dupon V, Arnaert S, Van Haute E, Vulsteke F, Diet G, De Schoenmakere G. Aseptic meningitis after SARS-CoV-2 Pfizer/BioNTech vaccination. Acta Clinica Belgica. 2022;77(6):976-9.
103. Zavari A, Hamidabad NM, Hassanzadeh M. Aseptic meningitis following AZD1222 COVID-19 vaccination. The American Journal of Emergency Medicine. 2022;55:225.e5-.e6.
104. Kang HS, Kim JE, Yoo JR, Oh H, Kim M, Kim YR, et al. Aseptic Meningitis Following Second Dose of an mRNA Coronavirus Disease 2019 Vaccine in a Healthy Male: Case Report and Literature Review. Infect Chemother. 2022;54(1):189-94.
105. Lee JK. Aseptic Meningitis Following the Second Dose of Comirnaty Vaccination in an Adolescent Patient: A Case Report. The Pediatric Infectious Disease Journal. 2022;41(2).
106. Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature medicine. 2021;27(12):2144-53.
107. Torrealba-Acosta G, Martin JC, Huttenbach Y, Garcia CR, Sohail MR, Agarwal SK, et al. Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine. BMJ Case Reports CP. 2021;14(7):e243173.
108. Zuhorn F, Graf T, Klingebiel R, Schäbitz WR, Rogalewski A. Postvaccinal Encephalitis after ChAdOx1 nCov-19. Annals of neurology. 2021;90(3):506-11.
109. Rinaldi V, Bellucci G, Romano A, Bozzao A, Salvetti M. ADEM after ChAdOx1 nCoV-19 vaccine: A case report. Multiple Sclerosis Journal. 2022;28(7):1151-4.
110. Al-Quliti K, Qureshi A, Quadri M, Abdulhameed B, Alanazi A, Alhujeily R. Acute Demyelinating Encephalomyelitis Post-COVID-19 Vaccination: A Case Report and Literature Review. Diseases. 2022;10(1):13.
111. Yazdanpanah F, Iranpour P, Haseli S, Poursadeghfard M, Yarmahmoodi F. Acute disseminated encephalomyelitis (ADEM) after SARS- CoV-2 vaccination: A case report. Radiology Case Reports. 2022;17(5):1789-93.
112. Cao L, Ren L. Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. Acta Neurologica Belgica. 2022;122(3):793-5.
113. Shyu S, Fan H-T, Shang S-T, Chan J-S, Chiang W-F, Chiu C-C, et al. Clinical Manifestation, Management, and Outcomes in Patients with COVID-19 Vaccine-Induced Acute Encephalitis: Two Case Reports and a Literature Review. Vaccines. 2022;10(8):1230.
114. Al-Mayhani T, Saber S, Stubbs MJ, Losseff NA, Perry RJ, Simister RJ, et al. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopaenia. Journal of Neurology, Neurosurgery & Psychiatry. 2021.
115. Taquet M, Husain M, Geddes JR, Luciano S, Harrison PJ. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. medRxiv. 2021.
116. Markus HS. Ischaemic stroke can follow COVID-19 vaccination but is much more common with COVID-19 infection itself. BMJ Publishing Group Ltd; 2021.
117. Kakovan M, Shirkouhi SG, Zarei M, Andalib S. Stroke associated with COVID-19 vaccines. Journal of Stroke and Cerebrovascular Diseases. 2022:106440.
118. Cabral G, Gonçalves C, Serrazina F, Sá F. MRI negative myelitis induced by Pfizer-BioNTech COVID-19 vaccine. Journal of Clinical Neurology (Seoul, Korea). 2022;18(1):120.
119. Dams L, Kraemer M, Becker J. MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination. Multiple Sclerosis Journal. 2022;28(7):1159-62.
120. Goss AL, Samudralwar RD, Das RR, Nath A. ANA investigates: neurological complications of COVID‐19 vaccines. Annals of neurology. 2021;89(5):856.
121. Lim E, Kim YH, Jeong N-Y, Kim S-H, Won H, Bae J-S, et al. The association between acute transverse myelitis and COVID-19 vaccination in Korea: Self-controlled case series study. European Journal of Neurology. 2025;32(1):e70020.
122. Kildegaard H, Ladebo L, Andersen JH, Jensen PB, Rasmussen L, Damkier P, et al. Risk of appendicitis after mRNA COVID-19 vaccination in a Danish population. JAMA internal medicine. 2022;182(6):684-6.
123. Mitchell J, Yue Q-Y. Appendicitis as a possible safety signal for the COVID-19 vaccines. Vaccine: X. 2021;9:100122.
124. FDA Staff Find Few Faults with Pfizer-BioNTech COVID-19 Vax December 8, 2020 [Available from:https://www.medpagetoday.com/infectiousdisease/covid19/90088.
125. Ramson DM, Gao H, Penny-Dimri JC, Liu Z, Khong JN, Caruana CB, et al. Duration of post-operative antibiotic treatment in acute complicated appendicitis: systematic review and meta-analysis. ANZ J Surg. 2021;91(7-8):1397-404.
126. Shahmoradi MK, Zarei F, Beiranvand M, Hosseinnia Z. A retrospective descriptive study based on etiology of appendicitis among patients undergoing appendectomy. International Journal of Surgery Open. 2021;31:100326.
127. Téoule P, Laffolie J, Rolle U, Reissfelder C. Acute Appendicitis in Childhood and Adulthood. Dtsch Arztebl Int. 2020;117(45):764-74.
128. Kawano H, Yamamoto N, Kurohama H, Okano S, Kurobe M, Honda T, et al. Fulminant Myocarditis and Acute Appendicitis after COVID-19 Vaccination. Intern Med. 2023;62(3):411-7.
129. Marconi E, Crescioli G, Bonaiuti R, Pugliese L, Santi R, Nesi G, et al. Acute appendicitis in a patient immunised with COVID-19 vaccine: A case report with morphological analysis. Br J Clin Pharmacol. 2023;89(2):551-5.
130. Oganesyan A, Schäfer M, Lesh C. Acute appendicitis following the COVID-19 vaccine. Journal of Surgical Case Reports. 2022;2022(6).
131. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. The New England journal of medicine. 2021;385(12):1078-90.
132. Ljung R, Pihlström N, Sundström A. Risk of appendicitis after SARS-CoV-2 infection and SARS-CoV-2 vaccination. Br J Surg. 2022;109(8):775-6.
133. Muhammad Yusoff F, Wong KK, Mohd Redzwan N. Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity. 2020;53(1):8-20.
134. Quint E, Kukeev I, Hazan I, Grupel D, Dukhno O, Osyntsov A, et al. Clinical characteristics of SARS-CoV-2 vaccine-related acute appendicitis. Can J Surg. 2023;66(3):E304-e9.
135. Mj EO, Juanes de Toledo B. Pfizer-BioNTech, la primera vacuna ARNm contra la COVID-19, parece segura y eficaz.
136. Wong CKH, Mak LY, Au ICH, Lai FTT, Li X, Wan EYF, et al. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. Journal of hepatology. 2022;77(5):1339-48.
137. Hines A, Shen JG, Olazagasti C, Shams S. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine. BMJ Case Reports CP. 2021;14(7):e242678.
138. Shlomovitz E, Davies W, Cairns E, Brintnell WC, Goldszmidt M, Dresser GK. Severe necrotizing pancreatitis following combined hepatitis A and B vaccination. Cmaj. 2007;176(3):339-42.
139. Bizjak M, Bruck O, Praprotnik S, Dahan S, Shoenfeld Y. Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry. Immunologic research. 2017;65(1):164-7.
140. COVID P-B. vaccine (BNT162, PF-07302048). Vaccines and Related Biological Products Advisory Committee briefing document. December 10, 2020.
141. Ozaka S, Kodera T, Ariki S, Kobayashi T, Murakami K. Acute pancreatitis soon after COVID-19 vaccination: A case report. Medicine. 2022;101(2).
142. Cahuapaza-Gutierrez NL, Pajuelo-Vasquez R, Quiroz-Narvaez C, Rioja-Torres F, Quispe-Andahua M, Runzer-Colmenares FM. Acute abdomen following COVID-19 vaccination: a systematic review. Clin Exp Vaccine Res. 2024;13(1):42-53.
143. Giles C. Covid-19 vaccines and periods. New Scientist. 2021;250(3341):14.
144. Kurdoğlu Z. Do the COVID-19 Vaccines Cause Menstrual Irregularities?
145. Zauche LH, Wallace B, Smoots AN, Olson CK, Oduyebo T, Kim SY, et al. Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21. 2021.
146. Girardelli S, Mullins E, Lees CC. COVID-19 and pregnancy: lessons from 2020. Early Human Development. 2021:105460.
147. Leclerc S, Royal V, Lamarche C, Laurin L-P. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report. American Journal of Kidney Diseases. 2021.
148. Ruebner RL, Fadrowski JJ. Tubulointerstitial nephritis. Pediatric Clinics. 2019;66(1):111-9.
149. Sowpati DT, Munigela A, Banu S, Siva AB, Sasikala M, Nutalapati C, et al. Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2. medRxiv. 2021.
150. Chauhan S, Meshram HS, Kute V, Patel H, Banerjee S, Engineer D, et al. SARS-CoV-2 infection in chronic kidney disease patients vaccinated with Oxford/AstraZeneca COVID-19 vaccine: initial Indian experience. Clinical Kidney Journal. 2021.
151. Anderegg MA, Liu M, Saganas C, Montani M, Vogt B, Huynh-Do U, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney international. 2021.
152. Holzworth A, Couchot P, Cruz-Knight W, Brucculeri M. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine. Kidney international. 2021;100(2):463-4.
153. Salem F, Rein J, Yu SM-W, Abramson M, Cravedi P, Chung M. Report of Three Cases of Minimal Change Disease Following the Second Dose of mRNA SARS-CoV-2 Vaccine. Kidney International Reports. 2021.
154. Izzedine H, Bonilla M, Jhaveri KD. Nephrotic syndrome and vasculitis following SARS-CoV-2 Vaccine: True association or circumstantial? Nephrol Dial Transplant. 2021:gfab215.
155. Lebedev L, Sapojnikov M, Wechsler A, Varadi-Levi R, Zamir D, Tobar A, et al. Minimal change disease following the Pfizer-BioNTech COVID-19 Vaccine. American Journal of Kidney Diseases. 2021.
156. Mancianti N, Guarnieri A, Tripodi S, Salvo DP, Garosi G. Minimal change disease following vaccination for SARS-CoV-2. Journal of Nephrology. 2021:1-2.
157. Weijers J, Alvarez C, Hermans MM. Post-vaccinal minimal change disease. Kidney International. 2021;100(2):459-61.
158. Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. American Journal of Kidney Diseases. 2021.
159. D’Agati VD, Kudose S, Bomback AS, Adamidis A, Tartini A. Minimal Change Disease and AKI following the Pfizer-BioNTech COVID-19 Vaccine. Kidney international. 2021.
160. Zhang J, Cao J, Ye Q. Renal Side Effects of COVID-19 Vaccination. Vaccines. 2022;10(11):1783.
161. Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2. Vaccines. 2021;9(6):572.
162. Rodríguez-Jiménez P, Chicharro P, Cabrera L-M, Seguí M, Morales-Caballero Á, Llamas-Velasco M, et al. Varicella-Zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Reports. 2021;12:58-9.
163. Cazzola M, Rogliani P, Mazzeo F, Matera MG. Controversy surrounding the Sputnik V vaccine. Respiratory medicine. 2021:106569.
164. Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5 vectored vaccines: a cautionary tale. The Lancet. 2020;396(10260):e68-e9.
165. Mishra SB, Mahendradas P, Kawali A, Sanjay S, Shetty R. Reactivation of varicella zoster infection presenting as acute retinal necrosis post COVID 19 vaccination in an Asian Indian male. European Journal of Ophthalmology. 2023;33(1):NP32-NP6.
166. Cabanillas B, Novak N. Allergy to COVID-19 vaccines: a current update. Allergology International. 2021;70(3):313-8.
167. Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines. 2021;9(3):221.
168. Lopes NT, Pinilla CEO, Gerbase AC. Erythema multiforme after CoronaVac vaccination. Journal of the European Academy of Dermatology and Venereology. 2021.
169. Farinazzo E, Ponis G, Zelin E, Errichetti E, Stinco G, Pinzani C, et al. Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from North‐East Italy. Journal of the European Academy of Dermatology and Venereology. 2021.
170. Capassoni M, Ketabchi S, Cassisa A, Caramelli R, Molinu AA, Galluccio F, et al. AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: A case report. Journal of Medical Virology. 2021;93(10):5718-20.
171. Cazzato G, Romita P, Foti C, Cimmino A, Colagrande A, Arezzo F, et al. Purpuric Skin Rash in a Patient Undergoing Pfizer-BioNTech COVID-19 Vaccination: Histological Evaluation and Perspectives. Vaccines. 2021;9(7):760.
172. Robinson LB, Fu X, Hashimoto D, Wickner P, Shenoy ES, Landman AB, et al. Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines. JAMA Dermatology. 2021;157(8):1000-2.
173. Abdulla ZA, Al-Bashir SM, Al-Salih NS, Aldamen AA, Abdulazeez MZ. A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development. Pathogens. 2021;10(7):788.
174. Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. Academic Radiology. 2021.
175. Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18 F] FDG PET-CT and relevance to study interpretation. European journal of nuclear medicine and molecular imaging. 2021;48:1854-63.
176. Ciliberti V, Maffei E, Giudice V, Ciancia G, Zeppa P, Caputo A. COVID-19 vaccine-associated lymphadenopathy: a review. Infez Med. 2024;32(2):119-30.
177. Juhel BC, Brunelle CL, Bernstein MC, Smith LH, Jung AW, Ababneh HS, et al. Side effects of COVID-19 vaccinations in patients treated for breast cancer. Clinical and Experimental Medicine. 2023:1-10.
178. (CDC) CfDPaC. Key things to know about COVID-19 vaccines. Accessed 29th May 2021.
179. (WHO) WHO. Covax. Accessed 28th May 2021.
180. Cines DB, Bussel JB. SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia. Mass Medical Soc; 2021.
181. Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet. 2021;397(10269):72-4.
182. Torjesen I. Covid-19: Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds. BMJ: British Medical Journal (Online). 2021;373.
| Files | ||
| Issue | Vol 7, No 3 (2024) | |
| Section | Review Article | |
| DOI | https://doi.org/10.18502/igj.v7i3.17877 | |
| Keywords | ||
| COVID-19 Mortality Morbidity Side Effect SARS-CoV-2 Vaccine | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Moghaddam S, Sheikh M, Khazeei Tabari MA, Darzi P, Rafiaei M, Sheikh M. Life-Threatening COVID-19 Vaccine-Related Side Effects: Are They Noteworthy?. Immunol Genet J. 2024;7(3):99-116.
